(Q38009713)

26 August 2017

title

Neuroprotection in diabetic retinopathy (English)

1 reference

26 August 2017

Cristina Hernández

1

1 reference

26 August 2017

Rafael Simó

series ordinal

2

1 reference

26 August 2017

publication date

1 August 2012

1 reference

26 August 2017

published in

Current diabetes report

1 reference

26 August 2017

volume

12

1 reference

26 August 2017

issue

4

1 reference

26 August 2017

page(s)

329-337

1 reference

https://scigraph.springernature.com/pub.10.1007/s11892-012-0284-5

26 August 2017

exact match

0 references

cites work

Burden of illness of diabetic macular edema: literature review

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Diabetic retinopathy in 2011: further insights from new epidemiological studies and clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Economic outcomes associated with microvascular complications of type 2 diabetes mellitus: results from a US claims data analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Prevalence and healthcare costs of diabetic retinopathy: a population-based register study in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Advances in the medical treatment of diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Benefits and limitations in vitreoretinal surgery for proliferative diabetic retinopathy and macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Retinal neurodegeneration: early pathology in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Early cellular and molecular changes induced by diabetes in the retina

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

A new view of diabetic retinopathy: a neurodegenerative disease of the eye.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

A role for the polyol pathway in the early neuroretinal apoptosis and glial changes induced by diabetes in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Diabetic retinopathy: seeing beyond glucose-induced microvascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Neuronal and glial cell abnormality as predictors of progression of diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

The significance of vascular and neural apoptosis to the pathology of diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Lower somatostatin expression is an early event in diabetic retinopathy and is associated with retinal neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Interphotoreceptor retinoid-binding protein (IRBP) is downregulated at early stages of diabetic retinopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Electrical responses from diabetic retina

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

A multifocal electroretinogram model predicting the development of diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Adolescents with Type 2 diabetes: early indications of focal retinal neuropathy, retinal thinning, and venular dilation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Multifocal electroretinograms predict onset of diabetic retinopathy in adult patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Expression of glutamate receptors and calcium-binding proteins in the retina of streptozotocin-induced diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

A role for excitatory amino acids in diabetic eye disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Diabetic retinal neurodegeneration is associated with mitochondrial oxidative stress and is improved by an angiotensin receptor blocker in a model combining hypertension and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Hyperglycaemia-induced pro-inflammatory responses by retinal Müller glia are regulated by the receptor for advanced glycation end-products (RAGE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Angiotensin and diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Angiotensin II type 1 receptor signaling contributes to synaptophysin degradation and neuronal dysfunction in the diabetic retina

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

AT1 receptor inhibition prevents astrocyte degeneration and restores vascular growth in oxygen-induced retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Neurodegeneration: An early event of diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Ladostigil prevents gliosis, oxidative-nitrative stress and memory deficits induced by intracerebroventricular injection of streptozotocin in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Aldose reductase deficiency prevents diabetes-induced blood-retinal barrier breakdown, apoptosis, and glial reactivation in the retina of db/db mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Effect of memantine on neuroretinal function and retinal vascular changes of streptozotocin-induced diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Signalling within the neurovascular unit in the mammalian retina

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Vasoregression linked to neuronal damage in the rat with defect of polycystin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Gene Expression Profiling of Vasoregression in the Retina—Involvement of Microglial Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Pharmacological Inhibition of N-Methyl D-Aspartate Receptor Promotes Secretion of Vascular Endothelial Growth Factor in Müller Cells: Effects of Hyperglycemia and Hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Inhibition of vitreoretinal VEGF elevation and blood-retinal barrier breakdown in streptozotocin-induced diabetic rats by brimonidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Diffuse luminance flicker increases retinal vessel diameter in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Visually evoked hemodynamical response and assessment of neurovascular coupling in the optic nerve and retina

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Flicker light-induced retinal vasodilation in diabetes and diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Differentiation of bone marrow-derived endothelial progenitor cells is shifted into a proinflammatory phenotype by hyperglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Neuroprotective and antiangiogenic actions of PEDF in the eye: molecular targets and therapeutic potential.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Physiology and pathology of somatostatin in the mammalian retina: a current view.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Deficit of somatostatin-like immunoreactivity in the vitreous fluid of diabetic patients: possible role in the development of proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Somatostatin molecular variants in the vitreous fluid: a comparative study between diabetic patients with proliferative diabetic retinopathy and nondiabetic control subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Activation of somatostatin receptor (sst 5) protects the rat retina from AMPA-induced neurotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Strategies for blocking angiogenesis in diabetic retinopathy: from basic science to clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Circulating IGF-I and its protective role in the pathogenesis of diabetic angiopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Erythropoietin and the hypoxic brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Erythropoietin--an endogenous retinal survival factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Neuroprotection of photoreceptors by direct delivery of erythropoietin to the retina of the retinal degeneration slow mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

ERK- and Akt-dependent neuroprotection by erythropoietin (EPO) against glyoxal-AGEs via modulation of Bcl-xL, Bax, and BAD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Expression of erythropoietin and its receptor in the human retina: a comparative study of diabetic and nondiabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Erythropoietin and VEGF exhibit equal angiogenic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Vitreous levels of erythropoietin in patients with macular oedema secondary to retinal vein occlusions: a comparative study with diabetic macular oedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Intravitreal injection of erythropoietin protects both retinal vascular and neuronal cells in early diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Erythropoietin protects retinal pigment epithelial cells against the increase of permeability induced by diabetic conditions: essential role of JAK2/ PI3K signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Feasibility of intravitreal erythropoietin injections in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Effects of intravitreal erythropoietin therapy for patients with chronic and progressive diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Lipid metabolites in the pathogenesis and treatment of neovascular eye disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Neurotrophins induce neuroprotective signaling in the retinal pigment epithelial cell by activating the synthesis of the anti-inflammatory and anti-apoptotic neuroprotectin D1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Peroxisome proliferator-activated receptor-α activation attenuates 3-nitropropionic acid induced behavioral and biochemical alterations in rats: possible neuroprotective mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Alpha2 adrenergic modulation of NMDA receptor function as a major mechanism of RGC protection in experimental glaucoma and retinal excitotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent: an evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

New techniques for drug delivery to the posterior eye segment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: Implications for glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0284-5

Cost savings associated with detection and treatment of diabetic eye disease

21 January 2018

1 reference

12 December 2020

Effect of pigment epithelium derived factor on the expression of glutamine synthetase in early phase of experimental diabetic retinopathy

1 reference

12 December 2020

Lowered cortistatin expression is an early event in the human diabetic retina and is associated with apoptosis and glial activation

1 reference

12 December 2020

Protection against methylglyoxal-derived AGEs by regulation of glyoxalase 1 prevents retinal neuroglial and vasodegenerative pathology

1 reference

12 December 2020

Does insulin-like growth factor I predict incidence and progression of diabetic retinopathy?

1 reference

12 December 2020

Somatostatin receptor 2A expression in choroidal neovascularization secondary to age-related macular degeneration.

1 reference

12 December 2020

Erythropoietin deficiency decreases vascular stability in mice.

1 reference

12 December 2020

Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment.

1 reference

12 December 2020

Erythropoietin: when liability becomes asset in neurovascular repair

1 reference

12 December 2020

Seeing beyond retinopathy in diabetes: electrophysiological and psychophysical abnormalities and alterations in vision

1 reference

12 December 2020

1 reference

12 December 2020

Long-term Treatment with Suberythropoietic Epo is Vaso- and Neuroprotective in Experimental Diabetic Retinopathy

1 reference

12 December 2020

Management of diabetic retinopathy: a systematic review

1 reference

12 December 2020

Deficit of somatostatin in the vitreous fluid of patients with diabetic macular edema

1 reference

12 December 2020

Targeting intraocular neovascularization and edema--one drop at a time

1 reference

12 December 2020

Erythropoietin is expressed in the human retina and it is highly elevated in the vitreous fluid of patients with diabetic macular edema

1 reference

12 December 2020

Erythropoietin is highly elevated in vitreous fluid of patients with proliferative diabetic retinopathy

1 reference

12 December 2020

Glial reactivity, an early feature of diabetic retinopathy.

1 reference

12 December 2020

10.1007/S11892-012-0284-5

Identifiers

DOI

1 reference

Dimensions Publication ID

26 August 2017

1035101016

0 references

1 reference